Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Amortizatization of Intangibles: 2015-2025

Historic Amortizatization of Intangibles for Spyre Therapeutics (SYRE) over the last 10 years, with Sep 2025 value amounting to $1.4 million.

  • Spyre Therapeutics' Amortizatization of Intangibles fell 55.01% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.4 million, marking a year-over-year decrease of 21.20%. This contributed to the annual value of $11.4 million for FY2024, which is 391.98% up from last year.
  • Per Spyre Therapeutics' latest filing, its Amortizatization of Intangibles stood at $1.4 million for Q3 2025, which was down 32.94% from $2.0 million recorded in Q2 2025.
  • In the past 5 years, Spyre Therapeutics' Amortizatization of Intangibles ranged from a high of $3.6 million in Q2 2024 and a low of -$181,000 during Q1 2021.
  • Moreover, its 3-year median value for Amortizatization of Intangibles was $2.0 million (2025), whereas its average is $1.8 million.
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first tumbled by 1,700.00% in 2021, then soared by 6,258.93% in 2024.
  • Quarterly analysis of 5 years shows Spyre Therapeutics' Amortizatization of Intangibles stood at -$58,000 in 2021, then spiked by 281.03% to $105,000 in 2022, then skyrocketed by 1,524.76% to $1.7 million in 2023, then surged by 41.79% to $2.4 million in 2024, then crashed by 55.01% to $1.4 million in 2025.
  • Its Amortizatization of Intangibles stands at $1.4 million for Q3 2025, versus $2.0 million for Q2 2025 and $2.6 million for Q1 2025.